Lumacaftor / Ivacaftor combo for DF508 > 12yrs

The Pulmonary-Allergy Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) held a hearing on May 12 to discuss Vertex Pharmaceuticals’ new drug application for approval of the lumacaftor/ivacaftor combination therapy for the treatment of cystic fibrosis in patients age 12 years and older who are homozygous for the F508del mutation.

This is one issue we should be following closely. We’ll keep you updated as soon as we have some news on the outcome of that meeting.

Tell us what you think

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s